Evidence map›Paper›PMID 42430873›Full record

ArticleVaccine2026

COVID-19 vaccination among people with HIV in Uganda: lessons from a high-risk group with high vaccine uptake for the next pandemic.

Taing Nandi Aung, Winnie Muyindike, Susanne S Hoeppner, Victoria Nanfuka, Nimusiima Komukama, Ian T Barigye, Justus Tumusiime, Daniel Omoding, Lyra S Johnson, Ashley Stuckwisch and 8 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04066036 (Population Effectiveness of Dolutegravir Implementation in Sub-Saharan Africa), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04066036 completednot on this map

Population Effectiveness of Dolutegravir Implementation in Sub-Saharan Africa: A Prospective Observational Cohort Study

TypeobservationalSponsorMassachusetts General HospitalRan2019 to 2023Enrolled999ConditionsHIV-1-infectionArmsThis is an observational study only.
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Taing Nandi AungMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA.
Winnie MuyindikeMbarara University of Science and Technology, Mbarara, Uganda.
Susanne S HoeppnerMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Victoria NanfukaMbarara University of Science and Technology, Mbarara, Uganda.
Nimusiima KomukamaMbarara University of Science and Technology, Mbarara, Uganda.
Ian T BarigyeMbarara University of Science and Technology, Mbarara, Uganda.
Justus TumusiimeMbarara University of Science and Technology, Mbarara, Uganda.
Daniel OmodingMbarara University of Science and Technology, Mbarara, Uganda.
Lyra S JohnsonMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA.
Ashley StuckwischMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA.
Jodian A PinkneyHarvard Medical School, Boston, MA, USA; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.
Bethany Hedt-GauthierUNC Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA.
Vincent C MarconiEmory University School of Medicine and Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Mahomed-Yunus S MoosaDepartment of Infectious Diseases, University of KwaZulu-Natal, Durban, South Africa.
Deenan PillayUniversity College London, London, United Kingdom.
Ravindra K GuptaUniversity of Cambridge, Cambridge, United Kingdom; Africa Health Research Institute, Durban, South Africa.
Mark J SiednerMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA; Africa Health Research Institute, Durban, South Africa.
Suzanne M McCluskeyMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA. Electronic address: smccluskey@mgh.harvard.edu.

Funding

Infant Immunization to Reduce Pneumonia in HIV +ve womenP30AI050409 · EMORY UNIVERSITY · 2002 to 2025
$11.1M
Virologic and pharmacologic determinants of dolutegravir failure in East AfricaK23AI143470 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Suzanne McCluskey · 2021 to 2023
$631k
Mentoring patient-oriented research to improve cardiovascular health among people with HIV in sub-Saharan AfricaK24HL166024 · MASSACHUSETTS GENERAL HOSPITAL · 2025 to 2025
$122k
NHLBI NIH HHS K24 HL166024NIAID NIH HHS K23 AI143470NIAID NIH HHS P30 AI050409
6 · The paper itself

Abstract

backgroundDespite the effectiveness of the COVID-19 vaccine, vaccination rates vary across settings and populations, especially among people living with HIV (PLHIV). We assessed factors associated with COVID-19 vaccination among PLHIV in Mbarara, Uganda.

methodsWe conducted a cross-sectional, secondary analysis of a prospective cohort study consisting of PLHIV ≥18 years old on antiretroviral therapy (ART). We collected data on COVID-19 vaccine uptake and associated factors beginning in December 2021, 9 months after the vaccine became available in Uganda. Reasons for vaccine acceptance and hesitancy were analyzed descriptively, while factors associated with vaccine uptake were assessed using Poisson models with robust standard errors.

resultsWe analyzed data from 449 participants with a mean age of 46 years (SD 9) and ART duration of 10 years (SD 4). 42% were female, 96% were virally suppressed (<50 copies/mL), and 83% (95% CI = 75%-92%) reported vaccination for COVID-19. In unadjusted analyses, greater concern about COVID-19, obtaining COVID-19 information from health resources, longer ART duration in years, and continuous access to soap and water were positively and significantly correlated with vaccine uptake (p < 0.05). Among those unvaccinated (n = 77/449, 17%), fear of side effects (n = 32/77, 42%) and beliefs that vaccination increased infection risk (n = 12/77, 16%) were predominant reasons for vaccine hesitancy.

conclusionsWe found high rates of COVID-19 vaccination among PLHIV on ART in Uganda. Among those unvaccinated, lack of confidence in the safety of the vaccine was the primary barrier to uptake. Future vaccine campaigns should emphasize vaccine safety and efficacy and actively combat misinformation to promote uptake. REGISTRY NUMBER: Clinical Trials Registration. NCT04066036.

Indexed as

COVID-19COVID-19 VaccinesHIV InfectionsVaccinationAdultCross-Sectional StudiesFemaleHumansMaleMiddle AgedPandemicsProspective StudiesSARS-CoV-2UgandaVaccination HesitancyCOVID-19 VaccinesCOVID-19HIV/AIDSUgandaVaccine hesitancy

Identifiers

PMID42430873
PMCPMC13459057

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.